The case for & against
Bull & Bear analysis
Bearish
Masimo Corporation (NASDAQ: MASI) is a leader in healthcare technology, specifically known for its innovative noninvasive monitoring solutions, including pulse oximetry systems. The company is currently focused on enhancing patient care while strategically transitioning back to its core healthcare business following the divestiture of its consumer sector. Masimo positions itself effectively within the healthcare segment, capitalizing on growing demand for advanced monitoring technologies amid ongoing economic pressures and competitive dynamics.
Bull says
- ↑Q1 healthcare revenue was $371 M (+10% YoY).
- ↑Non-GAAP EPS reached $1.36 (+56% YoY).
- ↑Operating margin expanded 750 bps to 28.8% via cost cuts.
- ↑Contract revenue hit $124 M (+48% YoY), boosting recurring sales.
- ↑Full-year revenue guided at $1.50–1.53 B (+8–11%).
- ↑Next-gen AI monitoring pipeline and Philips partnership drive market share.
Bear says
- ↓Tariffs risk cutting operating margins by 210–250 bps.
- ↓Consumer revenue fell 6% amid luxury spending weakness.
- ↓Post-divestiture shift to healthcare adds execution uncertainty.
- ↓Intense competition in monitoring tech pressures market share.
- ↓Revenue sensitive to hospital census and tender timing.
- ↓Elevated costs and mixed factor outlook heighten downside risk.
Investment themes with MASI
Medical Devices↓ -0.50%
Devices and instruments for medical treatment
ISRG · ABT · SYK
Earnings Call · Q3 2024 · Mgmt. Guidance
Updated 09-09-2026neutral
Transcript signals
Bull points
- For the third quarter, our healthcare revenues were $343 million, which is near the top end of our guidance range, and represented 12% growth versus last year.
- For our consolidated business, non-GAAP operating profit was $81 million, representing 23% growth versus last year. Our operating margin of 16% improved 230 basis points year over year and rose 130 basis points sequentially from the second quarter. This represents a very strong result considering that we overcame 480 basis points of year-over-year expense headwinds due to the return of performance-based compensation to normal levels in 2024.
- Even with the return of performance-based compensation, we delivered 31% EPS growth to reach non-GAAP earnings per share of 98 cents for the third quarter, which was primarily driven by strong performance from our healthcare business and effective expense management across the organization.
Bear points
- Non healthcare revenues were 161 million, which was near the low end of our guidance range and represented a 6% decline versus the prior year. This business continues to be affected by the weakening environment for luxury consumer purchases, as well as slowness in the housing market, which affects product installations and upgrades.
- For the non-healthcare segment, we are projecting revenues of $218 million to $238 million, which represents a decrease of $20 million at the midpoint versus the prior guidance range.
- For the non-healthcare segment, we are now projecting revenues of $685 million to $705 million, which represents a decrease of $20 million at the midpoint versus the prior guidance range.
Read full transcript analysis ›